Premium
research paper: Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia
Author(s) -
Moreno Daniel Antunes,
Scrideli Carlos Alberto,
Cortez Maria Angélica Abdala,
De Paula Queiroz Rosane,
Valera Elvis Terci,
Da Silva Silveira Vanessa,
Yunes José Andres,
Brandalise Silvia Regina,
Tone Luiz Gonzaga
Publication year - 2010
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2010.08301.x
Subject(s) - hdac3 , hdac4 , medicine , real time polymerase chain reaction , oncology , gene expression , cancer research , histone deacetylase 2 , immunology , histone , biology , gene , histone deacetylase , genetics
Summary Altered expression of histone deacetylases (HDACs) is a common feature in several human malignancies and may represent an interesting target for cancer treatment, including haematological malignancies. We evaluated the mRNA gene expression profile of 12 HDAC genes by quantitative real‐time polymerase chain reaction in 94 consecutive childhood acute lymphoblastic leukaemia (ALL) samples and its association with clinical/biological features and survival. ALL samples showed higher expression levels of HDAC2, HDAC3, HDAC8, HDAC6 and HDAC7 when compared to normal bone marrow samples. HDAC1 and HDAC4 showed high expression in T‐ALL and HDAC5 was highly expressed in B‐lineage ALL. Higher than median expression levels of HDAC3 were associated with a significantly lower 5‐year event‐free survival (EFS) in the overall group of patients ( P = 0·03) and in T‐ALL patients ( P = 0·01). HDAC7 and HADC9 expression levels higher than median were associated with a lower 5‐year EFS in the overall group ( P = 0·04 and P = 0·003, respectively) and in B‐lineage CD10‐positive patients ( P = 0·009 and P = 0·005, respectively). Our data suggest that higher expression of HDAC7 and HDAC9 is associated with poor prognosis in childhood ALL and could be promising therapeutic targets for the treatment of refractory childhood ALL.